{"id":25588,"date":"2025-06-03T12:43:07","date_gmt":"2025-06-03T10:43:07","guid":{"rendered":"https:\/\/www.izb-online.de\/protevo-bio-uebernimmt-plattformtechnologien-zur-skalierbaren-proteinproduktion\/"},"modified":"2025-06-03T13:01:21","modified_gmt":"2025-06-03T11:01:21","slug":"protevo-bio-acquires-platform-technologies-for-scalable-protein-production","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/izb-biotech-news\/protevo-bio-acquires-platform-technologies-for-scalable-protein-production\/","title":{"rendered":"Protevo Bio Acquires Platform Technologies for Scalable Protein Production"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text css=”” el_class=”gco-magazine–title”]<\/p>\n

Protevo Bio Acquires Platform Technologies for Scalable Protein Production<\/h1>\n

[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-lead”]With acquired know-how and innovative technology, Protevo Bio is entering a new era of scalable protein production.[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine–post-date”]June, 2025[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”two-columns” el_id=”corona-ausblenden”][vc_column_inner el_class=”bild-zwei-spalten-links”][vc_single_image image=”6283″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]The Lungs[\/vc_column_text][vc_single_image image=”6285″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 Pieris[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]Stephen S. Yoder<\/strong>, CEO, Pieris Pharmaceuticals Inc.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”25586″ img_size=”full” css=””][vc_column_text css=”” el_class=”gco-magazine-copyright”]\u00a9 Protevo Bio[\/vc_column_text][vc_column_text css=”” el_class=”gco-magazine-picture-discription”]Protevo Bio develops scalable and cost-effective purification processes for proteins[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text css=””]<\/p>\n

\u201eWe are delighted that the investor and entrepreneur consortium sees great potential in Protevo Bio’s technology.\u201c<\/h6>\n

Christian Gnam, Managing Director of the Innovation and Start-up Center Biotechnology (IZB)<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text css=””]Munich-based Protevo Bio, a newly formed, IZB-based consortium of investors and entrepreneurs, acquired key assets from the insolvent mk2 Biotechnologies, which enable large-scale and cost-effective production of highly pure proteins. Additionally intangible assets were transferred along with key know-how carriers and consolidated under a new roof. The R&D site at the IZB in Martinsried is also retained.<\/strong><\/p>\n

“We are pleased with the tremendous trust placed in us by investors, service providers, and customers, among others, which has allowed us to assemble a strong team behind Protevo Bio and thus respond to the rapidly changing market environment,” says Dr. Konstantinos Antonopoulos, CEO of Protevo Bio. “In particular, the employees and their enormous experience remain a fundamental component of our outstanding technology toolbox for cost-effective protein purification.” Protevo Bio will commercialize the platform technologies, which enable chromatography-free and thus scalable and cost-effective protein purification, using a lean and goal-oriented strategy that includes, amongst others, the development and production of its own product portfolio. “Through this strategy, we have not only been able to preserve these exciting assets but also have an even stronger focus on the future, where we want to set new standards in protein production for cost-sensitive applications,”<\/em> adds the CEO.<\/p>\n

Christian Gnam, Managing Director of the Innovation and Start-up Center Biotechnology (IZB) in Munich\/Martinsried, where Protevo Bio maintains its R&D site, explains: “We are delighted that the investor and entrepreneur consortium sees great potential in Protevo Bio’s technology. Protevo Bio’s synergies with other companies at the IZB and the team’s expertise are an asset to our community and the biotech hub.”<\/em><\/p>\n

About Protevo Bio
\n<\/strong>Protevo Bio develops scalable and cost-effective purification processes for proteins. By combining these processes, particularly with recombinant production strains such as bacterial systems, yeasts, or cell lines, production processes are created that enable the efficient production of large batches and at consistently low costs. This paves the way for recombinant proteins to be used in cost-sensitive markets such as the food, animal health or biotools industries, for which conventional production methods have previously been too expensive. In addition, the simplicity of the processes allows for flexible responses to fluctuating demand and contributes to ensuring robust supply chains. Protevo Bio produces selected products in-house or develops customized processes for external partners.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n